Intraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I/II dose escalation and safety study—INTERACT MESO

INTRODUCTION: Malignant peritoneal mesothelioma (MPM) is a rare, aggressive tumour arising primarily from the peritoneum. The only potentially curative treatment is cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). However, the majority of patients are not eligible...

Descripción completa

Detalles Bibliográficos
Autores principales: van Kooten, Job P, Dietz, Michelle V, Guchelaar, Niels A D, Brandt-Kerkhof, Alexandra R M, Koolen, Stijn L W, Burger, Jacobus W A, Mathijssen, Ron H J, Verhoef, Cornelis, Aerts, Joachim G J V, Madsen, Eva V E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Surgery
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226944/
https://www.ncbi.nlm.nih.gov/pubmed/35732399
http://dx.doi.org/10.1136/bmjopen-2022-062907

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226944/
https://www.ncbi.nlm.nih.gov/pubmed/35732399
http://dx.doi.org/10.1136/bmjopen-2022-062907

Ejemplares similares